
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow Inc. is well-positioned to capitalize on the growing biosimilars market, which has seen over 40% market share in specific therapeutic categories since 2015, enhancing the company's competitive edge in the eyecare segment. The company's flagship product, VEVYE, demonstrated a notable revenue increase of 22% quarter-over-quarter, reaching $22.6 million in 3Q25, alongside a market share gain in the national dry eye disease market. Expectations for continued prescription growth momentum suggest that Harrow's quarterly revenue run rate could exceed $250 million by 4Q27, which would represent a substantial increase compared to previous financial performance, supporting a positive long-term outlook for the firm.
Bears say
Harrow Inc faces several fundamental risks that contribute to a negative outlook on its stock, including the potential failure of its spinout products to produce favorable clinical data or secure regulatory approval, which could significantly impair the company’s valuation. Additionally, the company's limited resources may hinder its ability to execute aggressive sales and marketing strategies, and there are looming concerns over cash flow given the potential need to raise capital, which may result in shareholder dilution. Furthermore, adverse market conditions, including lower-than-expected product adoption rates and the imposition of unfavorable regulations, could further strain the company’s operational viability and financial performance.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares